Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tuberculosis), is among the most serious infectious diseases worldwide. Adjuvanted protein subunit vaccines have been demonstrated as a kind of promising novel vaccine. This study proposed to investigate whether cytokines interliukine-7 (IL-7) and interliukine-15 (IL-15) help TB subunit vaccines induce long-term cell-mediated immune responses, which are required for vaccination against TB. In this study, mice were immunized with the M. tuberculosis protein subunit vaccines combined with adnovirus-mediated cytokines IL-7, IL-15, IL-7-IL-15, and IL-7-Linker-IL-15 at 0, 2, and 4 weeks, respectively. Twenty weeks after the last immunization, the long-term immune responses, especially the central memory-like T cells (TCM like cell)-mediated immune responses, were determined with the methods of cultured IFN-γ-ELISPOT, expanded secondary immune responses, cell proliferation, and protective efficacy against Mycobacterium bovis Bacilli Calmette-Guerin (BCG) challenge, etc. The results showed that the group of vaccine + rAd-IL-7-Linker-IL-15 induced a stronger long-term antigen-specific TCM like cells-mediated immune responses and had higher protective efficacy against BCG challenge than the vaccine + rAd-vector control group, the vaccine + rAd-IL-7 and the vaccine + rAd-IL-15 groups. This study indicated that rAd-IL-7-Linker-IL-15 improved the TB subunit vaccine’s efficacy by augmenting TCM like cells and provided long-term protective efficacy against Mycobacteria.

Highlights

  • Tuberculosis (TB), mainly caused by Mycobacterium tuberculosis (M. tuberculosis), ranks as the first leading cause of death from a single infectious disease worldwide [1]

  • These results indicated that IL-7-Linker-IL-15 promoted vaccine produce stronger immune stronger immune memory with higher protective efficacy than IL-7 and IL-15

  • Our study showed that rAd-IL-7-Linker-IL-15 promoted formation and maintenance TCM like cells and improved proliferative capability of TCM like cells, which resulted in stronger protective efficacy against Bacilli Calmette-Guerin (BCG)

Read more

Summary

Introduction

Tuberculosis (TB), mainly caused by Mycobacterium tuberculosis (M. tuberculosis), ranks as the first leading cause of death from a single infectious disease worldwide [1]. Bacilli Calmette-Guerin (BCG) is the only approved TB vaccine in clinic. It provides variable protection against TB [2,3]. There are reports that BCG vaccination mainly induces shorter-term effector memory T cells (TEM ) rather than long-lived central memory T cells (TCM ) [4,5].

Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call